Incubator Cohort - 2026

Bump is a music technology company building intuitive hardware and tools for the next generation of creators. Bump gives live music a digital brain, transforming analogue sound into music intelligence, powering solutions in Education, Performance, Live Experiences, and Creator Tools. Bump’s first product is Bump BPM, a beatmatching aid for Vinyl DJs, removing the fear that stops digital DJs from trying vinyl and gives experienced vinyl DJs accuracy and confidence.

Maxam Labs help bridge quantum theory to commercial reality. Quantum computers can solve complex problems exponentially faster than classical computers - but they are difficult to use, with high maintenance costs and error rates; preventing them delivering commercial value at scale. Maxam Labs are adapting Quorph – their proprietary artificial swarm intelligence to create an error correction/mitigation solution that is hardware agnostic, adapts quantum circuits in real time, and is expected to deliver up to a 75% reduction in error rates.

O-Innovations is developing a wind energy solution designed specifically for cities, where conventional turbines struggle with turbulent and changing airflow. Its technology captures wind generated around buildings to produce renewable electricity within existing urban infrastructure. By enabling more local generation, O-Innovations aims to reduce pressure on centralised grids and support cities in meeting their net-zero targets.

Protostem-AI is developing specialist project management software for stem cell research and manufacturing. The platform improves reproducibility, standardisation, and process control by supporting structured project design, continuous data monitoring with proactive analytics, and standardised data capture. By embedding best-practice guidance and strengthening documentation, Protostem-AI helps reduce experimental variability, minimise resource waste, improve regulatory readiness, and enable teams to operate more efficiently and reliably.

UNVEIL Therapeutics is developing an off-the-shelf DNA vaccine platform designed to improve how the immune system recognises and responds to solid tumours. Our lead candidate, UTX-001, targets multiple tumour-associated antigens in non-small cell lung cancer, with read-across potential to breast, prostate and colorectal cancers. Previous cancer vaccines have been limited by shifting tumour targets and shielding of tumours from immune attack, while personalised approaches remain slow, complex and hard to scale. UNVEIL's proprietary, immunology-informed approach removes tumour shielding and engineers therapies designed to work for all patients and adapt to a changing tumour environment. We are working with the University of Liverpool to shape our development and clinical pathway.